XML 32 R27.htm IDEA: XBRL DOCUMENT
v3.20.1

Acquisitions (Tables) | 9 Months Ended
--- | ---
Mar. 31, 2020
Business Combinations [Abstract] |
Summary of assets acquired and liabilities assumed | The Pediatric Portfolio
|  | As of |
|  | November 1, 2019 |
Consideration |  |  |
Cash and cash equivalents |  | $ | 4,500,000 |
Fair value of Series G Convertible Preferred Stock |  |  |  |
Total shares issued |  |  | 9,805,845 |
Estimated fair value per share of Aytu common stock |  | $ | 0.567 |
Estimated fair value of equity consideration transferred |  | $ | 5,559,914 |
Total consideration transferred |  | $ | 10,059,914 |
Recognized amounts of identifiable assets acquired and liabilities assumed |  |  |  |
Inventory, net |  | $ | 459,123 |
Prepaid assets |  |  | 1,743,555 |
Other current assets |  |  | 2,548,187 |
Intangible assets – product technology rights |  |  | 22,700,000 |
Accrued product program liabilities |  |  | (6,320,853 | )
Assumed fixed payment obligations |  |  | (26,457,162 | )
Total identifiable net assets |  | $ | (5,327,150 | )
Goodwill |  | $ | 15,387,064 |
Innovus Merger (Consumer Health Portfolio)
|  | As of |
|  | February 14, 2020 |
Consideration |  |  |
Fair value of Aytu Common Stock |  |  |
Total shares issued at close |  |  | 3,810,393 |
Estimated fair value per share of Aytu common stock |  | $ | 0.756 |
Estimated fair value of equity consideration transferred |  | $ | 2,880,581 |
Fair value of Series H Convertible Preferred Stock |  |  |  |
Total shares issued |  |  | 1,997,736 |
Estimated fair value per share of Aytu common stock |  | $ | 0.756 |
Estimated fair value of equity consideration transferred |  | $ | 1,510,288 |
Fair value of former Innovus warrants |  | $ | 15,315 |
Fair value of Contingent Value Rights |  | $ | 7,049,079 |
Forgiveness of Note Payable owed to the Company |  | $ | 1,350,000 |
Total consideration transferred |  | $ | 12,805,263 |
Recognized amounts of identifiable assets acquired and liabilities assumed |  |  |
Cash and cash equivalents |  |  | 390,916 |
Accounts receivables, net |  | $ | 278,826 |
Inventory, net |  |  | 1,149,625 |
Prepaid expenses and other current assets |  |  | 1,736,796 |
Other long-term assets |  |  | 36,781 |
Right-to-use assets |  |  | 328,410 |
Property, plant and equipment |  |  | 190,393 |
Trademarks and patents |  |  | 11,744,000 |
Accounts payable and accrued other expenses |  |  | (6,983,969 | )
Other current liabilities |  |  | (446,995 | )
Notes payable |  |  | (3,056,361 | )
Lease liability |  |  | (754,822 | )
Preacquisition contingent consideration |  |  | (182,606 | )
Total identifiable net assets |  |  | 4,430,994 |
Goodwill |  | $ | 8,374,269 |
Summary of intangible assets acquired | The Pediatric Portfolio
|  | As of November 1, 2019 |
Acquired product technology rights |  | $ | 22,700,000 |
Innovus Merger (Consumer Health Portfolio)
|  | As of February 14, 2020 |
Acquired product distribution rights |  | $ | 11,354,000 |
Acquired customer lists |  |  | 390,000 |
Total intangible assets |  | $ | 11,744,000 |
Pro forma information |
|  | Three Months Ended March 31, |  | Nine Months Ended March 31,
|  | 2020 |  | 2019 |  | 2020 |  | 2019
|  | Unaudited (aa) (bb) |  | Pro forma Unaudited |  | Pro forma Unaudited (cc) |  | Pro forma Unaudited
Total revenues, net |  | $ | 10,331,629 |  |  | $ | 10,575,866 |  |  | $ | 34,276,368 |  |  | $ | 36,916,501 |
Net income (loss) |  |  | (5,850,703 | ) |  |  | (8,740,850 | ) |  |  | (18,197,902 | ) |  |  | (17,205,490 | )
Net income / (loss) per share (dd) |  | $ | (0.17 | ) |  | $ | (0.39 | ) |  | $ | (0.80 | ) |  | $ | (0.76 | )
(aa) | For the three months ended March 31, 2020, Pediatric Portfolio acquisition occurred prior to the three months ended March 31, 2020, and accordingly, the results of the Pediatric Portfolio are fully consolidated into the Company’s results for the three months ended March 31, 2020.
(bb) | Due to the absence of discrete financial information for Innovus, covering the period from February 1, 2020 through February 13, 2020, the Company did not include the impact of that stub-period for the pro forma results for the three and nine months ended March 31, 2020.
(cc) | Due to a lack of financial information covering the period from October 1, 2019 through November 1, 2019, the Company was not able to provide pro forma adjusted financial statements for the nine months ended March 31, 2020 without making estimated extrapolations that the Company did not believe would be material or useful to users of the above pro forma information.
(dd) | Pro forma net loss per share calculations excluded the impact of the issuance of the (i) Series G Convertible Preferred Stock and the, (ii) Series H Convertible Preferred Stock under the assumption those shares would continue to remain non-participatory during the periods reported above.

X
- Definition Tabular disclosure of pro forma results of operations for a material business acquisition or series of individually immaterial business acquisitions that are material in the aggregate. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (h)(2) -URI http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (h)(3) -URI http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463 + Details
Name: | us-gaap_BusinessAcquisitionProFormaInformationTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_BusinessCombinationsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of finite-lived and indefinite-lived intangible assets acquired as part of a business combination. + References No definition available. + Details
Name: | us-gaap_FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 20 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=121647850&loc=d3e4845-128472 + Details
Name: | us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration